Literature DB >> 19756956

Neutral endopeptidase is a myristoylated protein.

Rong Zheng1, Akio Horiguchi, Katsuyuki Iida, Jungoo Lee, Ruoqian Shen, Oscar B Goodman, David M Nanus.   

Abstract

Neutral endopeptidase (NEP) is a cell-surface peptidase normally expressed by prostate epithelial cells and lost in ~50% of primary prostate cancers. NEP directly associates with multiple proteins at the cell surface including Ezrin/Radixin/Moesin (ERM) proteins and the PTEN tumor suppressor protein. Analysis of the N-terminal sequence of the NEP cytosolic domain (N-terminal MGKSESQMDI TDINTPKPKK KQRWTR) identified a myristoylation consensus site. Mutation of Gly-2 to Arg significantly decreased (3)H-myristoylation activity, and correlated with translocation of NEP from the plasma membrane to a perinuclear domain as demonstrated by immunofluorescence staining and Western blotting with an NEP-specific antibody. Removal of this myristoylation residue did not affect NEP enzymatic specific activity. Myristoylated NEP recruited more PTEN protein to the cell membrane fraction than unmyristoylated NEP. These data demonstrate that NEP is myristoylated at Gly-2 and that this modification is an intrinsic signal for membrane targeting.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19756956     DOI: 10.1007/s11010-009-0253-8

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  40 in total

1.  Oncogenic transformation induced by membrane-targeted Akt2 and Akt3.

Authors:  I Mende; S Malstrom; P N Tsichlis; P K Vogt; M Aoki
Journal:  Oncogene       Date:  2001-07-19       Impact factor: 9.867

Review 2.  Post-translational chemical modification(s) of proteins.

Authors:  K K Han; A Martinage
Journal:  Int J Biochem       Date:  1992

Review 3.  Protein N-myristoylation: simple questions, unexpected answers.

Authors:  J I Gordon
Journal:  Clin Res       Date:  1990-10

4.  Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling.

Authors:  M Sumitomo; R Shen; M Walburg; J Dai; Y Geng; D Navarro; G Boileau; C N Papandreou; F G Giancotti; B Knudsen; D M Nanus
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

5.  Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation.

Authors:  Takashi Saito; Nobuhisa Iwata; Satoshi Tsubuki; Yoshie Takaki; Jiro Takano; Shu-Ming Huang; Takahiro Suemoto; Makoto Higuchi; Takaomi C Saido
Journal:  Nat Med       Date:  2005-03-20       Impact factor: 53.440

6.  Expression and immunolocalisation of neutral endopeptidase in prostate cancer.

Authors:  Martin Albrecht; Anja Mittler; Beate Wilhelm; Ake Lundwall; Hans Lilja; Gerhard Aumüller; Anders Bjartell
Journal:  Eur Urol       Date:  2003-10       Impact factor: 20.096

7.  Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression.

Authors:  C N Papandreou; B Usmani; Y Geng; T Bogenrieder; R Freeman; S Wilk; C L Finstad; V E Reuter; C T Powell; D Scheinberg; C Magill; H I Scher; A P Albino; D M Nanus
Journal:  Nat Med       Date:  1998-01       Impact factor: 53.440

8.  Synergy in tumor suppression by direct interaction of neutral endopeptidase with PTEN.

Authors:  Makoto Sumitomo; Akira Iwase; Rong Zheng; Daniel Navarro; David Kaminetzky; Ruoqian Shen; Maria-Magdalena Georgescu; David M Nanus
Journal:  Cancer Cell       Date:  2004-01       Impact factor: 31.743

Review 9.  Neprilysin and amyloid beta peptide degradation.

Authors:  Louis B Hersh; David W Rodgers
Journal:  Curr Alzheimer Res       Date:  2008-04       Impact factor: 3.498

10.  Neutral endopeptidase protein expression and prognosis in localized prostate cancer.

Authors:  Iman Osman; Herman Yee; Samir S Taneja; Benjamin Levinson; Anne Zeleniuch-Jacquotte; Caroline Chang; Craig Nobert; David M Nanus
Journal:  Clin Cancer Res       Date:  2004-06-15       Impact factor: 12.531

View more
  1 in total

Review 1.  Neprilysin expression and functions in development, ageing and disease.

Authors:  N N Nalivaeva; I A Zhuravin; A J Turner
Journal:  Mech Ageing Dev       Date:  2020-09-26       Impact factor: 5.432

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.